Medtronic touted data last week for its Infuse bone graft that is not particularly positive for the product. Not only that, it heralded the release of the data as a paradigm-shifting event.
Industry analysts don’t expect that findings from two independent analyses of the product, based on raw data handed over by Medtronic, will be helpful to the marketing prospects of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?